Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.00.
A number of research firms have commented on IOVA. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Monday, August 12th. StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a research note on Monday, August 12th. JMP Securities dropped their price target on shares of Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating on the stock in a research note on Thursday, June 20th. Finally, Piper Sandler cut shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $19.00 to $10.00 in a research note on Monday, July 29th.
Get Our Latest Stock Report on IOVA
Institutional Investors Weigh In On Iovance Biotherapeutics
Iovance Biotherapeutics Trading Down 4.8 %
Shares of IOVA stock opened at $9.66 on Tuesday. Iovance Biotherapeutics has a 52 week low of $3.21 and a 52 week high of $18.33. The company has a market cap of $2.70 billion, a PE ratio of -5.37 and a beta of 0.63. The company’s fifty day simple moving average is $9.85 and its 200-day simple moving average is $10.60.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01. Iovance Biotherapeutics had a negative net margin of 1,343.27% and a negative return on equity of 65.04%. The company had revenue of $31.11 million during the quarter, compared to analysts’ expectations of $24.59 million. During the same period in the prior year, the company posted ($0.47) EPS. The firm’s revenue for the quarter was up 12969.7% on a year-over-year basis. Equities research analysts expect that Iovance Biotherapeutics will post -1.26 EPS for the current fiscal year.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Further Reading
- Five stocks we like better than Iovance Biotherapeutics
- Compound Interest and Why It Matters When Investing
- The Average 401k Balance by Age Explained
- What is the Nikkei 225 index?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the NASDAQ Stock Exchange?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.